Short-term observation of direct oral anticoagulant use in an atrial fibrillation patient with high bleeding risk and kidney transplant:a case report  

作　　者：Wei XIANG Ling-Yun KONG Jing BAI Jun-Jie XIE Fang LIU 

机构地区：[1]Department of Cardiology,Beijing Tsinghua Changgung Hospital,School of Clinical Medicine,Tsinghua University,Beijing,China [2]Department of Organ Transplant Center,Beijing Tsinghua Changgung Hospital,School of Clinical Medicine,Tsinghua University,Beijing,China

出　　处：《Journal of Geriatric Cardiology》2021年第8期692-696,共5页老年心脏病学杂志（英文版）

摘　　要：Kidney transplant(KTx)is considered to be the best treatment for end-stage renal diseases compared with hemodialysis or peritoneal dialysis,because it significantly im-proves renal function,reduces cardiovascular events and mortality,enhances quality of life and prolongs life expectancy.[1,2]Atrial fibrillation(AF)is frequently coexistent with KTx,and a higher risk will occur in KTx recipients with AF compared with those aren’t with AF.[3]Patients with AF are at risk of stroke,systemic emboli and death.It is recom-mended that high-risk AF patients should use oral anticoagulants for preventive treatment.Direct oral anticoagulants(DOACs),including dabigatran,rivaroxaban,apixaban and edoxaban,are widely recommended for use in the general population compared to vitamin K antagonists(VKA).

关 键 词：FIBRILLATION DIALYSIS KIDNEY 

分 类 号：R969.3[医药卫生—药理学]